Fujian Cosunter Pharmaceutical (300436.SZ): The GST-HG141 tablets have good safety and significant efficacy for patients with chronic hepatitis B low viral load syndrome.

Fujian Cosunter Pharmaceutical (300436.SZ) announced that its innovative hepatitis B drug GST-HG141 has completed Phase II clinical trials for Low Viral Load Hepatitis B (LLV) and recently received the research summary report for the Phase II clinical trials. The study results show that GST-HG141 tablets have good safety and significant efficacy for patients with chronic hepatitis B low viral load. The inhibitory effect on HBV DNA is significantly better than the recommended nucleos(t)ide analog monotherapy in clinical practice. The drug has been confirmed to further suppress HBV DNA replication and potentially deplete cccDNA on the basis of nucleos(t)ide analog drug treatment in hepatitis B patients, achieving the expected goals in clinical research with excellent data. GST-HG141 is a new type of hepatitis B core protein or nucleocapsid regulator, belonging to a new class of investigational drugs with a completely new mechanism for combating hepatitis B virus. So far, there are no similar products approved for sale globally.